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2Abstract
Vascular myocytes are central to brain aging. Small vessel disease (SVD; arteriolosclerosis)
is a widespread cause of lacunar stroke and vascular dementia, and is characterised by
fibrosis and depletion of vascular myocytes in small penetrating arteries. Vascular
endothelial growth factor (VEGF) is associated with brain aging, and VEGFR2 is a potent
determinant of cell fate. Here, we tested whether VEGFR2 in vascular myocytes is
associated with older age and SVD in human brain.
VEGFR2 immunolabelling in deep grey matter was assessed in older people with or without
moderate-severe SVD, or in younger people without brain pathology or with a monogenic
form of SVD (CADASIL). All cases were without Alzheimer’s disease pathology. Myocyte
VEGFR2 was associated with increasing age (p=0.0026) but not with SVD pathology or
with sclerotic index or blood vessel density. We conclude that VEGFR2 is consistently
expressed in small artery myocytes of older people, and may mediate effects of VEGF on
brain vascular aging.
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31. Introduction
Cerebral small vessel disease (SVD; arteriolosclerosis) is a widespread ageing-related
vasculopathy that causes lacunar stroke [13, 25], diffuse white matter lesions [31, 35] and
vascular cognitive impairment and dementia (VCID) [11, 17]. SVD is characterised by
fibrotic thickening in the wall of small penetrating arteries, with depletion of vascular
smooth muscle cells (VSMC) [18, 25, 26]. Though increasing age and high blood pressure
are risk factors for SVD, the molecular drivers for these cellular changes are unknown.
The trans-membrane tyrosine kinase-linked receptor VEGFR2 (also known as KDR or Flk-
1) is a potent determinant of cell fate [30, 41]. Activation of VEGFR2 in endothelial cells by
the canonical ligand VEGF is associated with angiogenesis and increased vascular
permeability. Within CNS tissues VEGFR2 has been reported in neurones [4, 6, 24, 27, 39],
oligodendrocyte progenitors [19], microglial cells [12] and in VSMC within spinal cord [6]
and retinal arteries [8]. The ligand VEGF is also expressed in brain tissue [3, 23, 38].
In adult brain VEGF is considered to play a role in neurorepair, following cerebrovascular
injury [15]. Following focal ischemia in cerebral cortex of non-human primates, VEGF and
VEGFR2 are both augmented [38, 39], and VEGF is elevated in cerebrospinal fluid (CSF) of
ischemic stroke patients[9]. A role for VEGF in age-related dementia also appears likely[23].
In a recent longitudinal study of older people, VEGF concentration in CSF was positively
associated with better brain aging outcomes, including episodic memory and executive
function [21].
Here we observed VEGFR2 in vascular smooth muscle cells (VSMC) within small
penetrating arteries in caudate-putamen of older people, a subcortical grey matter region
known to develop SVD [13, 25]. We hypothesized that VEGFR2 may influence cell fate in
the aging brain vasculature, and we therefore tested whether VEGFR2 in VSMC is
associated with age and with SVD.
2. Methods
2.1 Human brain tissue
4Post mortem brain tissue was obtained from: The Oxford Brain Collection, John Radcliffe
Hospital; and from Newcastle Brain Tissue Resource Centre, Newcastle upon Tyne. Brains
from older people (age at death: 65 y or more) were derived from the OPTIMA cohort [20].
Older people with neuropathological diagnosis of moderate-severe SVD were of average age
(± SD): 80.1 ± 10.7 y (range 66 – 99 y, n=15, 10 male:5 female). Older people without
neuropathological SVD: 79.5 ± 5.8 y (68 – 89 y, n=12, 6 male:6 female). Younger people
without brain pathology: 30.0 ± 12.3 y (male aged 11 y (M11), F26, M32, M40, F41).
CADASIL patients: 56.5 ± 9.9 y (F44, M55, M59, F68). This is a well-preserved tissue
cohort that we have examined previously [5, 14]. All tissue samples were donated following
written informed consent by donors or their next of kin. This study had approval of Local
Research Ethics Committees and the UK National Research Ethics Service.
We examined paraffin wax-embedded tissue blocks containing anterior caudate-putamen.
All brains were fixed in 10% neutral buffered formalin for at least 1 month, prior to wax
embedding. Mean post mortem delay was 42 ± 23 h (mean, SD; range 18 – 115 h) and mean
formalin time from post mortem examination to wax embedding was 6 ± 2 months (range: 1
– 9 mo). All cases were free from Alzheimer’s neuropathology as defined by CERAD
guidelines and NIA-Reagan designation. Three of the older SVD cases were
neuropathologically graded as Braak stage III/IV for Alzheimer Disease (AD)-related
neurofibrillary tangle pathology. All other cases were Braak stage ≤ II. In all cases, cerebral 
amyloid angiopathy was reported as “absent/mild”. CADASIL cases had typical SVD
pathology and there was no evidence of any other lesions, including AD type
neuropathology [42]. In all cases endothelia were positive for CD34 immunolabelling (not
shown), suggesting intact antigenicity.
2.2 Neuropathological assessment of SVD
SVD was defined on microscopic examination of standard haematoxylin and eosin sections
by a registered Neuropathologist (Dr C Joachim or MME), using a semi-quantitative
assessment scale [11]. SVD was defined as: widened perivascular spaces, or hyaline
thickening of arteriolar walls plus mild-moderate perivascular pallor of myelin staining, or
loosening with attenuation of nerve fibres with gliosis in white matter or loss of nerve cells
and gliosis in deep grey matter in one or more sections. Absence of SVD was defined as: no
widening of perivascular spaces or hyaline thickening of arteriolar walls, no perivascular
5pallor of myelin staining, loosening of tissue or attenuation of nerve fibres, or gliosis in
white matter, or loss of nerve cells and gliosis in deep grey matter [5, 11, 14].
2.3 Antibodies
VEGFR2 primary antibody (rabbit monoclonal; clone 55B11) was from Cell Signalling
Technology, Danvers, MA. The immunogen was a GST-fusion protein containing the C-
terminal 150 amino acids of human VEGFR2. This antibody detected a double band at the
appropriate molecular weight corresponding to VEGFR2 protein in Western blots, with
minimal background labelling, and did not cross-react with VEGF-R1 or VEGF-R3 [32].
CD34 antibody (clone QBend10, mouse monoclonal IgG1) was from Novocastra-Leica
Microsystems, Newcastle upon Tyne, UK. GFAP (rabbit polyclonal, Z0334) was from
Dako-Cytomation, Glostrup, Denmark and smooth muscle -actin (SMA; mouse
monoclonal, clone 1A4) was from Sigma-Aldrich, Poole, UK.
2.4 Immunohistochemistry
Paraffin wax embedded sections (6 µm) were de-waxed and processed for standard
immunohistochemical staining [5, 14]. After exposure to H2O2 (0.5 mol/L) to abolish
endogenous peroxidise activity and high-pressure heat-induced antigen retrieval (0.5 min,
120 oC, pH 7.8) sections were blocked with bovine serum albumen (BSA; 3 % w/v) in
phosphate-buffered saline containing 0.1 % v/v Triton-X100 (PBT). VEGFR2 primary
antibody was diluted (1:600) in PBT containing 3 % w/v BSA and applied to sections
overnight (4 oC). Other primary antibodies were applied for 60 min at room temperature:
CD34 (1:100), GFAP (1:10,000), smooth muscle -actin (1:500). Antibody labelling was
visualised using a peroxidise-conjugated secondary reagent and diaminobenzidine (DAB)
chromogen (Envision® kit, K4065, Dako, Carpinteria, CA), then counterstained with
Mayer’s haematoxylin. As a negative control neighbouring sections were treated without any
primary antibody or with irrelevant primary antibody (rabbit anti-sheep IgG, 1:100; BD-
Pharmingen).
2.5 Morphometric methods
DAB-labelled sections were examined on a Zeiss Axioplan-2 microscope driven by
Axiovision software (version 4.7). Within each VEGFR2-labelled section, all vessels of
arterial appearance with outer diameter between 20 and 200 µm, with a clear, non-inflected
6cross-sectional profile, were photographed in a blinded fashion. We term these vessels
“small arteries”, assumed to encompass arterioles. To assess the abundance of VEGFR2 in
myocytes, two blinded observers (FAJ; NSJ) independently scored the degree of
immunoreactivity as absent, sparse, moderate or abundant. VEGFR2 scoring was absolute
(not relative), in that no attempt was made to correct for reduced numbers of myocytes in a
given vessel. Of the 513 vessels graded, the two observers differed by at most one category
(on 65 vessels, 12.7 %), and for all these consensus was reached by discussion.
Sclerotic index (defined as 1 - inner diameter/outer diameter) is a measure of SVD severity
at the single-vessel level [14, 17, 26, 28]. Sclerotic index was determined for all vessels of
arterial appearance, cut with a clear circular profile, with outer diameter in the range 20-200
µm [17]. Sclerotic index < 0.3 corresponds to normal vessels without SVD; 0.3-0.5 to
moderate SVD; and >0.5 severe SVD [26, 28, 40].
2.6 Statistical analysis
Student unpaired t tests were used to test for significant differences (p<0.05) in continuous
variables (sclerotic index, age, post mortem interval) between groups. Mann-Whitney and
Kruskal-Wallis tests with Dunn’s post hoc corrections were used for categorical variables
(grades of VEGFR2 labelling).
3. Results
3.1 Histology and Immunohistochemistry
We examined caudate-putaminal tissue from 36 individuals. Older people (aged 65 y or
more) were categorised in terms of the presence or absence of neuropathological moderate-
severe SVD [11] referred to as SVD cases and aged controls (AC), respectively. Young
control cases (YC) were without SVD or other brain disease. CADASIL cases were
genetically confirmed for NOTCH3 mutations, as detailed previously [42].
In all tissue samples examined some capillaries were positive for VEGFR2 labelling (within
endothelial cells, examples in Figure 1A) though this was not universal, or widespread. This
labelling pattern was absent if primary antibody was omitted or an irrelevant primary
antibody was used (rabbit anti-sheep IgG, not shown). Within parenchymal tissue of older
7people (AC and SVD groups) some astrocytes were positive for VEGFR2 (Figure 1B).
VEGFR2 labelling in neurones was sparse (Figure 1A, B).
Cells in the medial layer of small vessels, with the appearance of VSMC, were frequently
positive for VEGFR2. These medial VEGFR2 positive cells were seen in small vessels of
older people, in CADASIL cases and in YC cases (Figure 1). Confocal imaging of tissue
sections double-labelled for VEGFR2 and the smooth muscle marker -actin (SMA)
confirmed co-labelling in VSMC of small arteries (Supplementary Figure S1).
3.2 Morphometric analysis
Degree of VEGFR2 labelling of VSMC in small arteries was graded on a categorical scale as
absent, sparse, moderate or abundant (examples in Figure S2). Across the four groups of
cases (YC, CADASIL, AC and SVD) there was a significant difference in degree of
VEGFR2 labelling (p=0.017; Figure 2A). There was no significant difference between AC
and SVD groups (p=0.463). Aged cases (pooling data from AC and SVD groups) had higher
median VEGFR2 score than younger cases (pooling YC and CADASIL groups) (Figure 2A;
p=0.0026, Mann-Whitney test).
Blood vessel density was assayed using densitometry software (see Supplementary file) in
neighbouring sections labelled with the endothelial marker CD34 and the VSMC marker
SMA. There was no significant difference in extent of CD34 or SMA labelling with respect
to degree of VEGFR2 labelling (p=0.432, 0.552 respectively).
Sclerotic index was higher in the SVD group relative to AC cases (p=0.045) and higher in
CADASIL than in YC cases (p=0.023, Figure 2B). Pooling data from all aged cases (AC,
SVD) sclerotic index did not differ in relation to VEGFR2 labelling grades (p=0.378, Figure
2C).
4. Discussion
Within adult CNS tissues the receptor VEGFR2 is seen in neurones of human, rat and
primate brain [4, 24, 27, 39, 41], in oligodendroglial progenitors [19], in human microglia
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small arteries of human spinal cord [6] and in blood vessels of peripheral tissues [8, 36, 37].
The ligand VEGF is also expressed in brain tissue [3, 23, 38]. Within adult brain VEGF was
detected in neurones and astrocytes [2, 4, 23, 27, 38].
The half-life of VEGFR2 protein is brief (a few hours) in cell culture systems [29, 36].
VEGFR2 transcriptional expression appears to be tightly controlled by multiple factors,
including the hypoxia-inducible factor HIF2a and VEGF itself. Following agonist (VEGFA)
binding and receptor activation, VEGFR2 is rapidly internalised from the plasmalemma and
degraded via a ubiquitin-dependent proteosomal pathway [10, 29]. Within native tissues the
rate of VEGFR2 protein turnover may be slower, dependent on local binding partners and
the degree of receptor activation [10, 29, 36].
The functional role of VEGFR2 within adult brain is unlikely to be angiogenic, as new
vessel growth is sparse in adult nervous tissue. This is supported by our finding that
endothelial VEGFR2 was not widespread. Physiological effects of VEGFR2 in adult brain
include migration of neuronal progenitor and oligodendrocyte progenitor cells [19, 41].
Following injury or in disease states, several functional roles for central VEGFR2 are
reported. Within multiple sclerosis lesions, endothelial VEGFR2 is induced by the
inflammatory cytokine IL-1β, and drives local blood-brain barrier permeability (due to 
endothelial claudin-5 breakdown) [1, 2]. VEGFR2 expression is strongly induced in VSMC
following IL-6 exposure [43], further supporting a role for VEGFR2 in the response to
neuroinflammatory stimuli [30, 41]. VEGFR2 is also upregulated following acute ischemic
challenge [15, 33, 39]. In cerebral cortical grey matter of non-human primates approximately
10 % of neurones were positive for VEGFR2, and this was enhanced following focal
ischaemia, both within the ischemic lesion and in distant neurones functionally connected to
the lesion site[39]. In the present study neuronal VEGFR2 labelling was rare, possibly
reflecting differences in species, chronological age and the brain regions examined (here, a
deep subcortical nucleus, the caudate-putamen).
Our finding of robust VEGFR2 expression in VSMC, a cell-type that is central to brain
vascular aging, invites speculation. Our data do not support association with blood vessel
density, or small vessel disease. Within experimental systems, the potent tyrosine kinase-
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phenotype of VSMC [7, 8, 22, 36, 37, 43]. In human aortic VSMC cultures, and in adult
mouse retina, VEGFR2 had a potent anti-migratory effect, mediated by VEGFR2-PDGFRβ 
receptor complexes [8]. In transgenic mice (VEGFδ/δ) lacking physiological levels of VEGF
expression, arterial VSMC lacked mature contractile phenotype, and their sympathetic
neuro-effector junctions were abnormal in structure and function [37]. VEGFδ/δ animals had
greatly impaired cerebral blood flow autoregulation, in response to a hypoxic challenge (4-
fold lower than wildtype mice) [37]. These data suggest that in adult brain arteries an
adequate level of VEGF is required to maintain VSMC in a stable, non-migratory state, and
in a fully-differentiated, contractile phenotype [8, 37].
We speculate that the VSMC-expressed VEGFR2 we observe may be under tonic activation
from centrally-produced VEGF. Previous work from cell culture and animal studies suggests
that this may be required for normal neurovascular coupling, and to maintain the stable non-
migratory, contractile phenotype of mature myocytes in penetrating small arteries [8, 37].
Myocyte VEGFR2 may also participate in VEGF-mediated actions in neurorepair, following
cerebrovascular injury [15, 33]. Brain protective actions of VEGF are suggested by findings
in mice [34] and human subjects [16, 21]. In a North American population of older people
(the Alzheimer's Disease Neuroimaging Initiative, or ADNI, cohort) VEGF concentration in
CSF was positively associated with better brain aging-related outcomes (hippocampal
atrophy, and composite measures of episodic memory and executive function)[21]. We
speculate that VEGFR2 in vascular myocytes may mediate some aspects of this protective
action of VEGF.
In conclusion, myocytes in small arteries were strongly positive for VEGFR2 in deep grey
matter of older people. The degree of expression was associated with age, and may be a
factor in vascular changes relevant to the aging brain.
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Figure Legends
Figure 1. VEGFR2 immunohistochemical labelling in human caudate-putamen.
A, VEGFR2 (brown) is seen in capillary endothelial cells. B, VEGFR2 is evident in
astrocytic cell bodies (arrows). In A and B large neuronal somata (N) are unlabelled. C, the
wall of a small artery (Ar) but not that of a neighbouring small vein (Ve) are strongly
positive for VEGFR2. D, in a small artery from a CADASIL case with severe fibrotic
thickening in the vessel wall (arrow shows acellular fibrous material), myocytes are strongly
positive for VEGFR2. E-H, VEGFR2 labelling in a small artery wall (panel E). This
overlaps with smooth muscle actin (SMA) in a neighbouring section (F), but not with
perivascular astrocyte labelling with GFAP (G). For orientation, a haematoxylin-eosin (HE)
labelled neighbouring section is shown. A-G, haematoxylin nuclear counterstain. A, E-H: 68
year old male, moderate SVD. B: female, aged 90 y, moderate SVD. D: male CADASIL
patient, age 55 y. Scale bars: 20 micron.
Figure 2. VEGFR2 labelling in relation to subject group, neuropathological SVD
severity and sclerotic index.
A, Median grade for myocyte VEGFR2 immunohistochemical labelling, compared across
four subject groups: young controls (YC), CADASIL cases, aged controls (AC) and aged
individuals with moderate-severe sporadic small vessel disease (SVD). Each symbol
represents a single subject. Horizontal lines mark the group median. Pooled older cases (AC,
SVD) had significantly higher median VEGFR2 grade than pooled younger cases (YC,
CADASIL). B, sclerotic index as a measure of single vessel wall thickening was compared
across patient groups. Horizontal lines mark the group mean. Mean sclerotic index was
higher in CADASIL than in YC cases, and higher in SVD than AC cases. Data from 511
vessels in total. C, sclerotic index did not differ across the different grades of myocyte
VEGFR2 labelling. Data shown only for aged cases (AC, SVD). Box-whiskers show
median, inter-quartile range and full range for each group. *p<0.05, ** p<0.01.
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Supplementary Methods
Multiple labelling immunofluorescence
Paraffin sections (6 μm thickness) were processed for immunofluorescence labeling as in our 
previous work, see [1, 3]. Heat-induced antigen retrieval was performed using a Menarini-
Biocare decloaker, (120oC, 30 s, in citrate buffer pH 6). Non-specific binding was blocked
by incubation with 3 % w/v BSA (Jackson Immunochemicals) in PBS-T for 1 hour at room
temperature. Sections were incubated overnight in a humidified chamber at 4oC with the
following primary antibodies: VEGF-R2 (1:100) and α-SMA (1:200), diluted in 3 % w/v 
BSA in PBS-T. Sections were incubated with appropriate secondary antibodies conjugated to
Alexa488 or Alexa546, diluted 1:200 in 3 % BSA in PBS-T at room temperature for 1 h.
After nuclear labeling with DAPI (30 min, 0.3 µM in PBS-T) sections were mounted and
photographed with a Zeiss LSM 510Meta confocal microscope. Red fluorescence was viewed
with 543 nm excitation and 545-575 nm emission bandwidth. Green fluorescence was viewed
with 488 nm excitation and 505-530 nm emission bandwidth. DAPI was viewed with 364 nm
excitation and 385-470 nm emission bandwidth. Neighboring sections were processed
identically in parallel, but with omission of primary antibodies.
Automated estimation of blood vessel density
Immunohistochemical labelling for CD34 and SMA (visualised with DAB chromogen) was
carried out on neighbouring sections from the same tissue block that was used for VEGF-R2.
Both CD34 and SMA revealed a fine network of mainly small vessels. TIFF images were
sampled at 4x magnification at 3 locations (as in our previous work)[2]. Briefly, the sections
were considered as being divided in three equal divisions, and the image sampled at the
centre of each division (avoiding tissue artefacts and large vessels). TIFF images were
colour-thresholded into haematoxylin and DAB components using the H-DAB macro within
ImageJ software, and the DAB (brown) area fractions obtained in ImageJ. An average of the
CD34 positive area fraction, and the SMA positive area fraction for the 3 images was
calculated in each case.
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Figure S1. Confocal immunofluorescence labelling of a small artery with VEGF-R2 and
the myocyte specific marker smooth muscle α-actin (SMA).  
A, B: VEGF-R2 labelling in the red channel (panel A) and SMA in the green channel (B).
The triple labelled image (panel C) shows clear overlap, denoted in yellow. The nuclear
counterstain is DAPI (blue). D: a neighbouring section treated identically but without primary
antibodies shows no cellular labelling. Some autofluorescence due to lipofuschin is seen,
most evident in the red channel, and some green fluorescence from fibrous elements in the
vessel wall in panel D. Scale bar: A-C: 20 microns, D: 100 microns.
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Figure S2. Examples of myocyte VEGF-R2 labelling grades in small arterial vessels.
A, myocyte labelling is absent (grade 0). B, sparse labelling (grade 1) in a convoluted
arteriole. C, moderate labelling (grade 2). D, abundant labelling (grade 3). Scale bar 20
microns.
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